Pixee Medical's Knee+ NexSight receives CE mark. Analyse what AR guidance offers over robotics in total knee arthroplasty and what questions remain.
CorVista Health presents machine-learned non-invasive INOCA detection data at ACC.26. Analysis of what this means for cardiology and women's heart care. Read more.
Spark Biomedical launches LUNA Phase II trial evaluating wearable auricular neurostimulation for heavy menstrual bleeding. What the study design reveals.
Roseman Bioventures launches in Las Vegas to accelerate biotech commercialization in Nevada. Read what this could mean for startups and the region.
Viz.ai’s new HCM studies suggest AI-ECG could improve detection and follow-up. Read what this changes for cardiology workflows and adoption.
Radiopharm Theranostics reports strong RAD 101 interim data in brain metastases imaging. Read expert analysis on clinical impact and regulatory outlook.
Spear Bio debuts BD-pTau 217, alpha-synuclein and pS129-a-syn assays at AD/PD 2026. What the claims mean for Alzheimer's and Parkinson's research. Read the analysis.
BostonGene presents multimodal AI CUP framework at USCAP 2026, identifying actionable targets in 65%+ of patients. Read the analysis.
GE HealthCare’s Photonova Spectra just won FDA clearance. Find out what this means for photon-counting CT, imaging workflows, and hospital adoption.
C2N's eMTBR-tau243 plasma assay shows independent prognostic value in Phase 3 Evoke data. What this means for Alzheimer's patient selection. Read the analysis.